These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

177 related items for PubMed ID: 15668194

  • 1. Characterization of a small molecule PAI-1 inhibitor, ZK4044.
    Liang A, Wu F, Tran K, Jones SW, Deng G, Ye B, Zhao Z, Snider RM, Dole WP, Morser J, Wu Q.
    Thromb Res; 2005; 115(4):341-50. PubMed ID: 15668194
    [Abstract] [Full Text] [Related]

  • 2. Identification of the binding site for a low-molecular-weight inhibitor of plasminogen activator inhibitor type 1 by site-directed mutagenesis.
    Björquist P, Ehnebom J, Inghardt T, Hansson L, Lindberg M, Linschoten M, Strömqvist M, Deinum J.
    Biochemistry; 1998 Feb 03; 37(5):1227-34. PubMed ID: 9477948
    [Abstract] [Full Text] [Related]

  • 3. Characterization and comparative evaluation of a novel PAI-1 inhibitor.
    Gils A, Stassen JM, Nar H, Kley JT, Wienen W, Ries UJ, Declerck PJ.
    Thromb Haemost; 2002 Jul 03; 88(1):137-43. PubMed ID: 12152654
    [Abstract] [Full Text] [Related]

  • 4. The variable region-1 from tissue-type plasminogen activator confers specificity for plasminogen activator inhibitor-1 to thrombin by facilitating catalysis: release of a kinetic block by a heterologous protein surface loop.
    Dekker RJ, Eichinger A, Stoop AA, Bode W, Pannekoek H, Horrevoets AJ.
    J Mol Biol; 1999 Oct 29; 293(3):613-27. PubMed ID: 10543954
    [Abstract] [Full Text] [Related]

  • 5. Evaluation of a low molecular weight modulator of human plasminogen activator inhibitor-1 activity.
    Charlton PA, Faint RW, Bent F, Bryans J, Chicarelli-Robinson I, Mackie I, Machin S, Bevan P.
    Thromb Haemost; 1996 May 29; 75(5):808-15. PubMed ID: 8725728
    [Abstract] [Full Text] [Related]

  • 6. Comparative analysis of the proteinase specificity in wild-type and stabilized plasminogen activator inhibitor-1: evidence for contribution of intramolecular flexibility.
    De Taeye B, Gils A, Vleugels N, Rabijns A, Declerck PJ.
    Biochem Biophys Res Commun; 2004 Aug 27; 321(3):746-51. PubMed ID: 15358169
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Plasminogen activator inhibitor type 2 inhibits cell surface associated tissue plasminogen activator in vitro: potential receptor interactions.
    Lobov S, Croucher DR, Saunders DN, Ranson M.
    Thromb Haemost; 2008 Aug 27; 100(2):319-29. PubMed ID: 18690354
    [Abstract] [Full Text] [Related]

  • 9. Binding areas of urokinase-type plasminogen activator-plasminogen activator inhibitor-1 complex for endocytosis receptors of the low-density lipoprotein receptor family, determined by site-directed mutagenesis.
    Skeldal S, Larsen JV, Pedersen KE, Petersen HH, Egelund R, Christensen A, Jensen JK, Gliemann J, Andreasen PA.
    FEBS J; 2006 Nov 27; 273(22):5143-59. PubMed ID: 17042782
    [Abstract] [Full Text] [Related]

  • 10. Different structural requirements for plasminogen activator inhibitor 1 (PAI-1) during latency transition and proteinase inhibition as evidenced by phage-displayed hypermutated PAI-1 libraries.
    Stoop AA, Eldering E, Dafforn TR, Read RJ, Pannekoek H.
    J Mol Biol; 2001 Jan 26; 305(4):773-83. PubMed ID: 11162091
    [Abstract] [Full Text] [Related]

  • 11. Distal hinge of plasminogen activator inhibitor-1 involves its latency transition and specificities toward serine proteases.
    Wang Q, Shaltiel S.
    BMC Biochem; 2003 Jul 08; 4():5. PubMed ID: 12848892
    [Abstract] [Full Text] [Related]

  • 12. The glycocalyx protects erythrocyte-bound tissue-type plasminogen activator from enzymatic inhibition.
    Ganguly K, Murciano JC, Westrick R, Leferovich J, Cines DB, Muzykantov VR.
    J Pharmacol Exp Ther; 2007 Apr 08; 321(1):158-64. PubMed ID: 17215448
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. TM5275 prolongs secreted tissue plasminogen activator retention and enhances fibrinolysis on vascular endothelial cells.
    Yasui H, Suzuki Y, Sano H, Suda T, Chida K, Dan T, Miyata T, Urano T.
    Thromb Res; 2013 Jul 08; 132(1):100-5. PubMed ID: 23611258
    [Abstract] [Full Text] [Related]

  • 16. Less pronounced enhancement of thrombin-dependent inactivation of plasminogen activator inhibitor type 1 by low molecular weight heparin compared with unfractionated heparin.
    Nakamura R, Umemura K, Hashimmoto H, Urano T.
    Thromb Haemost; 2006 Apr 08; 95(4):637-42. PubMed ID: 16601834
    [Abstract] [Full Text] [Related]

  • 17. Novel mechanism to enhance tPA-induced fibrinolysis: effect of limited proteolysis of PAI-1 by neutrophil elastase.
    Urano T, Wu K, Ihara H, Takada Y, Takada A.
    Pol J Pharmacol; 1996 Apr 08; 48(2):209-13. PubMed ID: 9112653
    [Abstract] [Full Text] [Related]

  • 18. The interaction between components of the fibrinolytic system and GPIb/V/IX of platelets thrombus formation in mice.
    Matsuno H, Kozawa O, Ueshima S, Matsuo O, Collen D, Uematsu T.
    Br J Pharmacol; 2000 Oct 08; 131(4):858-64. PubMed ID: 11030738
    [Abstract] [Full Text] [Related]

  • 19. VLHL plasminogen activator inhibitor spontaneously reactivates from the latent to active form.
    Jankun J, Aleem AM, Selman SH, Basrur V, Skrzypczak-Jankun E.
    Int J Mol Med; 2009 Jan 08; 23(1):57-63. PubMed ID: 19082507
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.